Spinocerebellar Ataxia Type 3 Clinical Trial
Official title:
The Treatment of Transcranial Alternating Current Stimulation(tACS)on Patients With Cerebellar Ataxia: A Randomized, Triple-blind, Parallel-controlled Study
This is a longitudinal, triple-blind, randomized-controlled, prospective observational study assessing patients with cerebellar ataxia, including spinocerebellar ataxia type 3 (SCA3) and multiple system atrophy-cerebellar type (MSA-C), to examine the efficacy, safety, and tolerability of transcranial alternating current stimulation (tACS) for up to 3 months.
Status | Recruiting |
Enrollment | 164 |
Est. completion date | March 31, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - for SCA3 - Patients with detectable clinical signs and confirmed genetic diagnosis with SCA3 - SCA3 patients aged 18 - 80 years - Patients or their family members have informed consent to the study and signed relevant documents - The pre-study ataxia Assessment Score (SARA) ranged from 3 to 30 - for MSA-C - Aged 30-80 years - Diagnosed as clinically determined (Established)MSA-C or clinically Probable MSA-C according to the latest MSA diagnostic criteria - No more than 4 years after diagnosis of MSA-C - Able to walk independently or with assistance - Have a life expectancy of at least 3 years - Women of childbearing age with MSA need to use contraceptive measures Exclusion Criteria: 1. Patients who have concomitant epilepsy. 2. Patients with a serious cognitive disorder, behavioral disorder, or mental illness 3. Patients with a history of seizures, stroke, encephalitis, or other degenerative neurological diseases 4. Patients with a serious medical disease - Patients who concomitantly suffer from severe renal impairment, convulsions, stomach ulcers, or moderate or more severe liver disease - Patients with uncontrolled high blood pressure or diabetes 5. History of head injury or neurosurgical interventions. 6. History of any metal in the head (outside the mouth). 7. Known history of any metallic particles in the eye, implanted cardiac pacemaker, implanted neurostimulators, surgical clips (above the shoulder line), or any medical pumps. 8. Patients who have taken other investigational products within 4 weeks before being enrolled in this clinical trial, or patients who are pregnant or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
China | Department of Neurology, The First Affiliated Hospital Fujian Medical University | Fuzhou | Fujian |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital of Fujian Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in Ataxia symptoms (Scale for the Assessment and Rating of Ataxia (SARA)) | To compare the proportion of patients with SARA improvement (decrease) of at least 1.5 from baseline after 2 weeks, assessing changes in the SARA Score | Baseline - 2 weeks | |
Primary | Changes of Clinical Evaluation from UMSARS (Unified Multiple System Atrophy Rating Scale) (only for MSA-C) | UMSARS I: This is an assessment of daily life activities via 12 items scale used to assess language, writing, autonomy, walking, and the presence of possible urinary, sexual, or intestinal disorders. (0=no disorder, 48=severe) UMSARS II: Motor examination based on 14 items that evaluate particular facial expression, oculomotricity, oral expression, tremors, or walking. 0=no disorder, 56=severe disorders.
UMSARS III: Blood pressure and heart rate measurements in lying and standing positions for 10 min every minute. UMSARS IV: Assessment of the disability from 1 to 5; 1 = completely independent; 5 = totally dependent. Changes of Clinical Evaluation for UMSARS improvement (decrease) from baseline to 2 weeks. |
Baseline - 2 weeks | |
Secondary | Changes in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline | ICARS: semi-quantitative 100-point scale, yielding a total score of 0 (no ataxia) to 100 (most severe ataxia) | Baseline - 2 weeks - 1 month - 3 months | |
Secondary | Changes in the Scale for the Assessment and Rating of Ataxia (SARA) Score From Baseline | SARA: 8-item performance-based scale, yielding a total score of 0 (no ataxia) to 40 (most severe ataxia) | Baseline - 2 weeks - 1 month - 3 months | |
Secondary | Changes in the 9 Hole Peg Test (9HPT) Score From Baseline | Three timed trials of 9HPT were performed and averaged (mean values are reported) for each separate hand (dominant and nondominant). The total time to complete the task will be recorded for each trial and each separate hand (dominant and nondominant). Longer times represent greater impairment. | Baseline - 2 weeks - 1 month - 3 months | |
Secondary | Hand Grip Strength | Baseline - 2 weeks - 1 month - 3 months | This is a basic force measurement of hand grip with a dynamometer. Hand grip strength is measured using the Jamar Grip. | |
Secondary | Pittsburgh Sleep Quality Index (PSQI) | The PSQI is the most commonly used instrument to assess the subjective sleep quality of adults in clinical and community settings. | Baseline - 2 weeks - 1 month - 3 months | |
Secondary | Epworth score | The Epworth auto-questionnaire, rated from 0 (better) to 24 (worse), assesses day-time sleepiness. | Baseline - 2 weeks - 1 month - 3 months | |
Secondary | Montreal Cognitive Assessment (MoCA) | In addressing cognitive screening tools, the MMSE and the MoCA are the most commonly used methods in detecting cognitive impairment detection in both clinical and research settings. | Baseline - 2 weeks - 1 month - 3 months | |
Secondary | Mini-Mental State Examination (MMSE) | In addressing cognitive screening tools, the MMSE and the MoCA are the most commonly used methods in cognitive impairment detection in both clinical and research fields. | Baseline - 2 weeks - 1 month - 3 months | |
Secondary | Hamilton Anxiety Scale (HAMA) | HAMA contains 14 questions; each question includes 5 items. Responses are scored as 0 (never), 1 (mild), 2 (moderate), 3 (severe), or 4 (extremely serious). The total score of HAMA is operationally categorized as follows: no anxiety (score 0-6), mild and moderate anxiety (score 7-13), and severe anxiety (score = 14). | Baseline - 2 weeks - 1 month - 3 months | |
Secondary | Hamilton Depression Scale (HAMD) | HAMD contains 17 questions; each question includes 5 items. Responses are scored as 0 (never), 1 (mild), 2 (moderate), 3 (severe), or 4 (extremely serious). The total score of HAMD can be classified into normal (score 0-6), mild and moderate (score 7-23), and severe depression (score = 24). | Baseline - 2 weeks - 1 month - 3 months | |
Secondary | Changes From Baseline in 5 Level EQ-5D (EQ-5D-5L) | The EQ-5D-5L is a standard measure of health-related quality of life. EQ-5D-5L consists of two components: a health state profile and a visual analog scale (VAS). EQ-5D health state profile comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where a higher score indicates a better health state. The VAS records the participant's health on a 0-100 mm VAS scale, with 0 indicating "the worst health you can imagine" and 100 indicating "the best health you can imagine." Higher scores of EQ-VAS indicate better health. | Baseline - 2 weeks - 1 month - 3 months | |
Secondary | Multiple System Atrophy Quality of Life (MSA-QoL) Score | The score of other sub-dimension of the MSA Quality of Life scale. The MSA-QoL questionnaire is composed of three different subscales: motor (14 items), non-motor (12 items), and emotional/social (14 items). The response options for each question range from 0 (no problem) to 4 (extreme problem), with higher total scores reflecting more impaired quality of life. The MSA-QoL also includes a visual analog scale (VAS) of how satisfied patients feel (range 0-100, with lower scores indicating a lower quality of life). | Baseline - 2 weeks - 1 month - 3 months | |
Secondary | Spatiotemporal dynamic changes measured with electroencephalography (EEG) | Changes in spatiotemporal dynamics in different frequency bands (theta, alpha, beta, gamma) will be assessed with high density-EEG after tACS intervention (gamma, sham) | Baseline - 2 weeks - 1 month - 3 months | |
Secondary | Changes from temporospatial parameters of gait | Gait parameters measured by Multimodal Gait Analysis System. The kinetic and kinematic data of gait will be collected in the gait analysis corridor using two sets of smart insole systems and two sets of gyroscope sensor systems. | Baseline-2 weeks - 1 month - 3 months | |
Secondary | Changes in Neuroimage changes in Magnetic Resonance Imaging (MRI) | Including T1, resting-state functional MRI, and Diffusional Kurtosis Imaging (DKI) | Baseline - 2 weeks - 1 month - 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00992771 -
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
|
Phase 2 | |
Completed |
NCT01096082 -
Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03701399 -
Troriluzole in Adult Subjects With Spinocerebellar Ataxia
|
Phase 3 | |
Active, not recruiting |
NCT04229823 -
Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD
|
||
Active, not recruiting |
NCT04419974 -
Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes
|
||
Terminated |
NCT05490563 -
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04301284 -
Study of CAD-1883 for Spinocerebellar Ataxia
|
Phase 2 | |
Withdrawn |
NCT01096095 -
Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
|
Phase 2 | |
Active, not recruiting |
NCT04268147 -
Instrumented Data Exchange for Ataxia Study
|
||
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Active, not recruiting |
NCT05826171 -
Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia
|
N/A | |
Recruiting |
NCT04399265 -
Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3
|
N/A | |
Completed |
NCT03885167 -
Identification of Biomarkers in Spinocerebellar Ataxia 3
|
||
Terminated |
NCT05160558 -
A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3
|
Phase 1 | |
Recruiting |
NCT05822908 -
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03378414 -
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
|
Phase 2 | |
Completed |
NCT05502432 -
Repetitive Transcranial Magnetic Stimulation in SCA3 Patients
|
N/A | |
Recruiting |
NCT04714307 -
Neuropsychiatry and Cognition in SCA3/MJD
|
||
Recruiting |
NCT01060371 -
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
|